1. Home
  2. SVM vs ORKA Comparison

SVM vs ORKA Comparison

Compare SVM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SVM

Silvercorp Metals Inc.

HOLD

Current Price

$8.90

Market Cap

1.4B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$31.70

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVM
ORKA
Founded
N/A
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SVM
ORKA
Price
$8.90
$31.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
10
Target Price
$9.00
$48.20
AVG Volume (30 Days)
5.7M
647.4K
Earning Date
02-10-2026
11-12-2025
Dividend Yield
0.28%
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$323,391,000.00
N/A
Revenue This Year
$22.28
N/A
Revenue Next Year
$32.53
N/A
P/E Ratio
$75.24
N/A
Revenue Growth
33.99
N/A
52 Week Low
$2.88
$5.49
52 Week High
$9.17
$32.64

Technical Indicators

Market Signals
Indicator
SVM
ORKA
Relative Strength Index (RSI) 66.09 59.40
Support Level $8.37 $27.84
Resistance Level $9.17 $32.64
Average True Range (ATR) 0.45 1.93
MACD -0.00 0.08
Stochastic Oscillator 79.79 80.73

Price Performance

Historical Comparison
SVM
ORKA

About SVM Silvercorp Metals Inc.

Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: